Tong L - Search Results

1

Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo.

Lai M, Zhang T, Chen H, Song P, Tong L, Chen J, Liu Y, Ning Y, Feng F, Li Y, Tang H, Chen Y, Fang Y, Lu X, Geng M, Ding K, Yu K, Ding J, Xie H. Lai M, et al. Among authors: tong l. J Cancer. 2023 Jan 1;14(1):152-162. doi: 10.7150/jca.77788. eCollection 2023. J Cancer. 2023. PMID: 36605493 Free PMC article.

2

Actinomycin D inhibiting K562 cell apoptosis elicited by salvicine but not decreasing its cytotoxicity.

Qing C, Miao ZH, Tong LJ, Zhang JS, Ding J. Qing C, et al. Acta Pharmacol Sin. 2003 May;24(5):415-21. Acta Pharmacol Sin. 2003. PMID: 12740176 Free article.

3

Characterization of salvicine-resistant lung adenocarcinoma A549/SAL cell line.

Miao ZH, Tong LJ, Zhang JS, Han JX, Ding J. Miao ZH, et al. Int J Cancer. 2004 Jul 10;110(5):627-32. doi: 10.1002/ijc.20026. Int J Cancer. 2004. PMID: 15146550

4

Anti-angiogenic effects of Shiraiachrome A, a compound isolated from a Chinese folk medicine used to treat rheumatoid arthritis.

Tong Y, Zhang X, Zhao W, Zhang Y, Lang J, Shi Y, Tan W, Li M, Zhang Y, Tong L, Lu H, Lin L, Ding J. Tong Y, et al. Among authors: tong l. Eur J Pharmacol. 2004 Jun 28;494(2-3):101-9. doi: 10.1016/j.ejphar.2004.04.053. Eur J Pharmacol. 2004. PMID: 15212963

5

Philinopside A, a novel marine-derived compound possessing dual anti-angiogenic and anti-tumor effects.

Tong Y, Zhang X, Tian F, Yi Y, Xu Q, Li L, Tong L, Lin L, Ding J. Tong Y, et al. Among authors: tong l. Int J Cancer. 2005 May 10;114(6):843-53. doi: 10.1002/ijc.20804. Int J Cancer. 2005. PMID: 15645493

6

Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin.

Tong YG, Zhang XW, Geng MY, Yue JM, Xin XL, Tian F, Shen X, Tong LJ, Li MH, Zhang C, Li WH, Lin LP, Ding J. Tong YG, et al. Mol Pharmacol. 2006 Apr;69(4):1226-33. doi: 10.1124/mol.105.020537. Epub 2006 Jan 19. Mol Pharmacol. 2006. PMID: 16424078

7

TKI-31 inhibits angiogenesis by combined suppression signaling pathway of VEGFR2 and PDGFRbeta.

Zhong L, Guo XN, Zhang XH, Sun QM, Tong LJ, Wu ZX, Luo XM, Jiang HL, Nan FJ, Zhang XW, Lin LP, Ding J. Zhong L, et al. Among authors: tong lj. Cancer Biol Ther. 2006 Mar;5(3):323-30. doi: 10.4161/cbt.5.3.2543. Epub 2006 Mar 23. Cancer Biol Ther. 2006. PMID: 16575201 Free article.

8

BM6, a new semi-synthetic vinca alkaloid, exhibits its potent in vivo anti-tumor activities via its high binding affinity for tubulin and improved pharmacokinetic profiles.

Li W, Shao Y, Hu L, Zhang X, Chen Y, Tong L, Li C, Shen X, Ding J. Li W, et al. Among authors: tong l. Cancer Biol Ther. 2007 May;6(5):787-94. doi: 10.4161/cbt.6.5.4006. Epub 2007 Feb 14. Cancer Biol Ther. 2007. PMID: 17387272 Free article.

9

Structural modification of an angiogenesis inhibitor discovered from traditional Chinese medicine and a structure-activity relationship study.

Yang SP, Cai YJ, Zhang BL, Tong LJ, Xie H, Wu Y, Lin LP, Ding J, Yue JM. Yang SP, et al. J Med Chem. 2008 Jan 10;51(1):77-85. doi: 10.1021/jm070906g. Epub 2007 Dec 14. J Med Chem. 2008. PMID: 18078313

10

Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species.

Lu JJ, Meng LH, Cai YJ, Chen Q, Tong LJ, Lin LP, Ding J. Lu JJ, et al. Cancer Biol Ther. 2008 Jul;7(7):1017-23. doi: 10.4161/cbt.7.7.6035. Epub 2008 Apr 4. Cancer Biol Ther. 2008. PMID: 18414062 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,871 results

Search Page

Filters